Immunovant Q3 net loss widens to $41.4M; cash at $527M; clinical pause continues

Immunovant, Inc.

2022-Q3 EPS reported -$1.02

Net loss of $41.4M ($0.36 per share) for Dec 2021 quarter vs. $31.8M ($0.32) a year ago.
R&D expenses rose to $29.8M from $21.1M, driven by clinical study costs and manufacturing.
Cash and equivalents of $527.0M as of Dec 31, 2021; no revenue reported.
G&A expenses increased to $11.5M from $10.5M year-over-year, partly due to stock-based compensation.
Clinical trial activities remain paused due to previously announced voluntary hold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.